회사 개요
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical entity based in the United States, focusing on developing and commercializing novel drug formulations for specific therapeutic indications. The company is situated within the broader Healthcare sector and specifically the Biotechnology industry, where it leverages research and development to advance product candidates such as PEDMARK, a formulation of sodium thiosulfate designed for the prevention of cisplatin-induced ototoxicity in pediatric patients. As of the latest reporting period, the company maintains a market capitalization of $220.64M and employs a workforce of 35 individuals to execute its commercial strategy. With reported trailing twelve-month revenue of $44.64M, the enterprise demonstrates a significant commercial footprint relative to its small employee base, indicating a high degree of operational efficiency or a capital-light business model common in the biotechnology space. The market capitalization figure reflects the aggregate market value of the company's equity, positioning it as a mid-cap player that balances early-stage innovation risks with established revenue streams from its current product portfolio.
재무 건전성
The company reported total revenue of $44.64M over the trailing twelve months, while net income stood at a loss of $9,741,000 and EBITDA recorded a loss of $6,179,333. The substantial gap between the $44.64M in revenue and the $9.74M net loss reveals a heavy cost structure characterized by high operating expenses that are not yet fully covered by gross profits, a typical characteristic for biotechnology firms in commercial transition. Free cash flow was reported at -$7,332,250, which indicates that the company is currently consuming cash to fund its operations and growth initiatives rather than generating surplus cash for shareholder returns or debt reduction. Despite the negative cash flow, the balance sheet remains robust with cash holdings of $36.79M against zero total debt, providing a significant liquidity buffer to sustain operations through the development and commercialization phases. The gross margin stands at an impressive 91.6%, suggesting high pricing power or low cost of goods sold, whereas the operating margin of -18.5% and profit margin of -21.8% highlight the intense investment required to scale commercial infrastructure. Short-term liquidity is exceptionally strong, evidenced by a current ratio of 6.37, which implies the company possesses ample current assets to cover its current liabilities many times over. Return on Equity is -65.8% and Return on Assets is -6.8%, metrics that reflect the dilution of existing shareholder equity and asset base due to ongoing losses, signaling that management is currently prioritizing growth and product expansion over immediate profitability.
밸류에이션 평가
Valuation metrics for Fennec Pharmaceuticals present a complex picture given the absence of traditional earnings-based multiples; the trailing P/E ratio is listed as N/A due to negative net income, while the forward P/E is 7.07, implying that the market expects earnings to turn positive or stabilize in the coming fiscal year. The price-to-book ratio of 6.17 suggests that the market values the company at a significant premium over its book value, likely reflecting the intrinsic worth of its intellectual property, clinical pipeline, and potential future cash flows. Alternative valuation measures include a price-to-sales ratio of 4.94 and an EV/EBITDA of -29.75, which indicates that investors are pricing the stock based on revenue generation rather than current profitability, a common practice for growth-oriented biotechs. The stock price has fluctuated between a 52-week low of $4.68 and a high of $9.92, with the current valuation sitting within this established trading range, reflecting market uncertainty regarding the timing of commercial success. The beta of 0.93 indicates that the stock's price volatility moves in tandem with the broader market, exhibiting slightly less sensitivity than the market average, which suggests a relatively stable risk profile for the sector.
Growth & Income
Revenue growth year-over-year accelerated to 73.8%, demonstrating strong top-line expansion, whereas earnings growth is listed as N/A due to the company's current unprofitable status. The lack of earnings growth data alongside strong revenue growth implies that the company is in an investment-heavy phase where revenue gains are not yet translating into bottom-line profits, a standard trajectory for commercial-stage biopharmaceutical companies. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash flows are internally reinvested into research, development, and commercial scaling efforts. This reinvestment strategy supports the aggressive revenue growth observed while deferring income generation to future periods when profitability is achieved. The overall growth and income profile is defined by high revenue expansion coupled with a complete absence of dividend income, positioning the asset primarily for capital appreciation potential rather than current yield generation.